
This interview highlights the long-term, late-breaking results of the A DUE trial’s 24-month open-label extension on macitentan and tadalafil for PAH.
Kelly M. Chin, MD, is a Professor of Internal Medicine and Director of Pulmonary Hypertension Clinical Research at UT Southwestern Medical Center.

This interview highlights the long-term, late-breaking results of the A DUE trial’s 24-month open-label extension on macitentan and tadalafil for PAH.